Drug Trial Radar · NCT06438757
Trial of JYB1904 in Patients With Allergic Asthma
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Jun 19, 2024
Primary completion
Nov 20, 2025
Study completion Dec 20, 2025
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.
Conditions
- Allergic Asthma
Interventions
JYB1904Drug
Participants will receive JYB1904 every 8 weeks for 24 weeks.
OmalizumabDrug
Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum concentrations of JYB1904Time frame: Baseline through 337 days post-dose
- Serum concentrations of IgETime frame: Baseline through 337 days post-dose
- Adverse Events(AEs)Time frame: Baseline through 337 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.